協和キリンの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2018/01/25 | 2,236 | 2,241 | 2,211 | 2,214 | -33 | -1.5% | 1,035,600 |
2018/01/24 | 2,212 | 2,253 | 2,206 | 2,247 | +22 | +1% | 939,900 |
2018/01/23 | 2,194 | 2,229 | 2,187 | 2,225 | +44 | +2% | 794,100 |
2018/01/22 | 2,158 | 2,181 | 2,147 | 2,181 | +22 | +1% | 526,100 |
2018/01/19 | 2,166 | 2,177 | 2,146 | 2,159 | +3 | +0.1% | 871,300 |
2018/01/18 | 2,223 | 2,227 | 2,147 | 2,156 | -22 | -1% | 1,501,400 |
2018/01/17 | 2,178 | 2,185 | 2,163 | 2,178 | -20 | -0.9% | 1,021,600 |
2018/01/16 | 2,205 | 2,210 | 2,191 | 2,198 | -7 | -0.3% | 836,500 |
2018/01/15 | 2,215 | 2,217 | 2,177 | 2,205 | -10 | -0.5% | 1,133,900 |
2018/01/12 | 2,241 | 2,249 | 2,213 | 2,215 | -41 | -1.8% | 1,222,200 |
2018/01/11 | 2,259 | 2,272 | 2,247 | 2,256 | -17 | -0.7% | 1,010,400 |
2018/01/10 | 2,294 | 2,306 | 2,271 | 2,273 | -8 | -0.4% | 826,000 |
2018/01/09 | 2,321 | 2,328 | 2,273 | 2,281 | -22 | -1% | 891,600 |
2018/01/05 | 2,300 | 2,306 | 2,259 | 2,303 | +22 | +1% | 1,289,700 |
2018/01/04 | 2,222 | 2,282 | 2,216 | 2,281 | +102 | +4.7% | 1,556,400 |
2017/12/29 | 2,183 | 2,199 | 2,167 | 2,179 | -3 | -0.1% | 642,600 |
2017/12/28 | 2,195 | 2,211 | 2,177 | 2,182 | +26 | +1.2% | 854,700 |
2017/12/27 | 2,164 | 2,168 | 2,149 | 2,156 | -17 | -0.8% | 506,300 |
2017/12/26 | 2,155 | 2,184 | 2,154 | 2,173 | +14 | +0.6% | 613,600 |
2017/12/25 | 2,160 | 2,164 | 2,147 | 2,159 | +12 | +0.6% | 277,700 |
2017/12/22 | 2,120 | 2,149 | 2,118 | 2,147 | +6 | +0.3% | 755,100 |
2017/12/21 | 2,147 | 2,149 | 2,122 | 2,141 | -7 | -0.3% | 736,500 |
2017/12/20 | 2,150 | 2,160 | 2,142 | 2,148 | -11 | -0.5% | 567,500 |
2017/12/19 | 2,190 | 2,190 | 2,155 | 2,159 | -30 | -1.4% | 898,700 |
2017/12/18 | 2,185 | 2,199 | 2,176 | 2,189 | +30 | +1.4% | 852,500 |
2017/12/15 | 2,160 | 2,177 | 2,145 | 2,159 | -5 | -0.2% | 1,163,500 |
2017/12/14 | 2,173 | 2,178 | 2,152 | 2,164 | +41 | +1.9% | 1,162,300 |
2017/12/13 | 2,121 | 2,136 | 2,114 | 2,123 | +13 | +0.6% | 1,029,700 |
2017/12/12 | 2,118 | 2,128 | 2,100 | 2,110 | -19 | -0.9% | 811,000 |
2017/12/11 | 2,091 | 2,129 | 2,089 | 2,129 | +53 | +2.6% | 905,200 |
2017/12/08 | 2,051 | 2,077 | 2,041 | 2,076 | +25 | +1.2% | 1,712,100 |
2017/12/07 | 2,013 | 2,059 | 2,012 | 2,051 | +48 | +2.4% | 1,223,500 |
2017/12/06 | 2,080 | 2,080 | 2,000 | 2,003 | -75 | -3.6% | 1,714,300 |
2017/12/05 | 2,056 | 2,090 | 2,052 | 2,078 | +3 | +0.1% | 862,300 |
2017/12/04 | 2,122 | 2,123 | 2,068 | 2,075 | -48 | -2.3% | 1,244,300 |
2017/12/01 | 2,150 | 2,156 | 2,103 | 2,123 | -6 | -0.3% | 1,159,800 |
2017/11/30 | 2,105 | 2,132 | 2,093 | 2,129 | +36 | +1.7% | 1,382,300 |
2017/11/29 | 2,095 | 2,104 | 2,076 | 2,093 | +7 | +0.3% | 1,008,900 |
2017/11/28 | 2,044 | 2,088 | 2,042 | 2,086 | +42 | +2.1% | 1,106,700 |
2017/11/27 | 2,057 | 2,073 | 2,036 | 2,044 | -24 | -1.2% | 1,088,500 |
2017/11/24 | 2,055 | 2,075 | 2,038 | 2,068 | -12 | -0.6% | 1,117,300 |
2017/11/22 | 2,125 | 2,138 | 2,076 | 2,080 | -30 | -1.4% | 1,287,800 |
2017/11/21 | 2,110 | 2,123 | 2,101 | 2,110 | -10 | -0.5% | 1,193,100 |
2017/11/20 | 2,149 | 2,156 | 2,114 | 2,120 | -44 | -2% | 1,039,600 |
2017/11/17 | 2,200 | 2,227 | 2,152 | 2,164 | -9 | -0.4% | 1,817,700 |
2017/11/16 | 2,074 | 2,178 | 2,074 | 2,173 | +109 | +5.3% | 1,650,800 |
2017/11/15 | 2,084 | 2,095 | 2,063 | 2,064 | -30 | -1.4% | 1,260,500 |
2017/11/14 | 2,089 | 2,119 | 2,079 | 2,094 | +5 | +0.2% | 1,001,800 |
2017/11/13 | 2,090 | 2,107 | 2,076 | 2,089 | -14 | -0.7% | 804,900 |
2017/11/10 | 2,096 | 2,114 | 2,070 | 2,103 | -13 | -0.6% | 1,486,200 |
1851~
1900
件表示中 / 3768件
類似銘柄と比較する
現在ご覧いただいている「協和キリン」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
協和キリン | 263,900円 | -3.5% | -11.3% | 2.27% | 24.24倍 | 1.64倍 |
|
キリン傘下。医薬品、バイオが主力。独自の抗体高活性化技術に強み。富士フイルムと提携 |
アステラス薬 | 169,200円 | +0.9% | +380.2% | 4.61% | 23.31倍 | 2.00倍 |
|
医薬品国内2位。開発技術起点の研究開発体制。前立腺がん薬が柱。遺伝子・細胞治療技術育成 |
塩野義 | 258,000円 | +20.9% | +10.6% | 2.56% | 12.20倍 | 1.61倍 |
|
抗HIV薬が大型製品に。感染症、疼痛・中枢神経領域に強み。米国に積極展開。欧州、アジア開拓 |
エーザイ | 467,600円 | +0.1% | -3.4% | 3.42% | 31.79倍 | 1.57倍 |
|
神経系、がん領域に強み。認知症薬は米バイオジェンと、抗がん薬では米メルクと国際協業推進 |
小野薬 | 166,100円 | +0.6% | +43.3% | 4.82% | 11.65倍 | 1.00倍 |
|
医療用医薬品専業の中堅。自社開発品多い。先駆的がん免疫阻害剤「オプジーボ」が成長牽引 |
市場注目の銘柄
チャート関連のコラム